Madri­gal's stock soars on promis­ing PhII da­ta in NASH, but ques­tions linger

The stock is fly­ing for Madri­gal Phar­ma­ceu­ti­cals fol­low­ing news that its fat­ty liv­er dis­ease drug suc­cess­ful­ly pared down liv­er fat in Phase II tri­als. Shares …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.